Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized Medicine

5 (2 votes)

Recorded On: 11/09/2018

This program will detail recent advances in the understanding of genetic and epigenetic alterations that influence NAFLD and its progression. It will emphasize their impact on the natural history of NAFLD and variability in clinical outcomes. Details on how patient based epigenetic association studies have led to novel insights into disease pathogenesis will be outlined with an emphasis on how this may translate to new therapeutics. Finally, the role of genetics and epigenetics in the evaluation of the patient in the clinic will be addressed – with particular reference to diagnosis, prognosis and therapeutics.

Elizabeth Speliotes

Christopher Glass

Derek Mann

Luca Valenti

Key:

Complete
Failed
Available
Locked
Introduction
Open to view video.
Open to view video.
Insights into Disease Pathogenesis from Population Genetic Studies
Open to view video.
Open to view video. Presenter: Elizabeth Speliotes,
Epigenomic Regulation of Inflammation in NASH
Open to view video.
Open to view video. Presenter: Christopher Glass
Discussion/ Q&A
Open to view video.
Open to view video.
Epigenetics: Modifiers and Therapeutic Targets of Disease Progression in NAFLD
Open to view video.
Open to view video. Presenter: Derek Mann
Genetics and Epigenetics in the Clinic: Personalized Medicine in the Management of NAFLD
Open to view video.
Open to view video. Presenter: Luca Valenti
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.